Trials / Conditions / Influenza Infection

Influenza Infection

21 registered clinical trials studyying Influenza Infection — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challe NCT07215871	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Recruiting	In-depth Analysis of the Immune Responses in the Upper Respiratory Tract of Influenza-infected Children NCT06998264	University Hospital, Geneva	—
Recruiting	In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized NCT06998251	University Hospital, Geneva	—
Completed	Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model NCT05436444	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4 NCT05818124	Merck Sharp & Dohme LLC	Phase 1
Terminated	Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transp NCT04933968	AlloVir	Phase 1 / Phase 2
Unknown	DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) NCT04298060	Ansun Biopharma, Inc.	Phase 2
Completed	Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy A NCT03814720	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult NCT03784885	Advagene Biopharma Co. Ltd.	Phase 2
Completed	Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants NCT02555618	Takeda	Phase 2
Completed	Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants NCT02367885	Takeda	Phase 1 / Phase 2
Completed	Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults NCT02313155	Takeda	Phase 1 / Phase 2
Unknown	Gargling With Green Tea for Prophylaxis of Influenza Infection in Teenagers NCT01225770	University of Shizuoka	Phase 3
Completed	Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device NCT01049490	The University of Hong Kong	N/A
Completed	Effects of Tea Catechin Consumption on the Prophylaxis of Influenza Infection NCT01008020	Masahiro Morikawa	N/A
Completed	A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine NCT01201902	Green Cross Corporation	Phase 3
Completed	Catechin Containing Mask for the Prevention of Influenza Infection NCT00812448	University of Shizuoka	N/A
Completed	Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine NCT00559975	Novartis	Phase 1
Completed	Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults NCT00603811	VaxInnate Corporation	Phase 1
Completed	Catechin Gargling for Influenza Infection NCT00239213	University of Shizuoka	N/A
Terminated	Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer NCT00647465	Assistance Publique - Hôpitaux de Paris	Phase 3